About the Research Group
We are studying molecules and their receptors, immune cells and carcinoma-associated fibroblasts to determine what significance they have in tumor growth, metastasis and patient survival. Molecular mechanisms of prognostic significance for cancer patients are central in our research. By comparing the prevalence of these molecules with clinical data from each patient, we can obtain important information on prognosis and therapeutic effects. The projects are based on tissue microarray (TMA) and in vitro studies on cells from resected cancer tissues.
Our research activity is primarily based on tumor tissue from lung, prostate, breast and soft tissue sarcomas and the focus is on the following common mechanisms in cancer:
- Angiogenesis, hypoxia and metabolism switch
- The role of the immune system in the tumor microenvironment
- Epithelial mesenchymal transition (EMT)
The molecular investigations are on DNA, RNA, microRNA and protein level using polymerase chain reaction (PCR), in situ hybridization (ISH), microarray, and immunohistochemistry (IHC).
In addition, we use commercial lung cancer cell cultures and short term cultures established from freshly resected lung cancers to study cancer-associated fibroblasts (CAFs) survival mechanisms and contributing role with respect to angiogenesis and tumor growth after radiation. The secretory profile is examined and functional assays performed.
The objective of our clinical cancer research group is through multi-center clinical trials to identify more optimal therapy for cancer patients, both with regard to side effects and efficacy.
The long-term aim of our research group is to identify novel potential molecular targets for future anticancer agents.